Nerisona (Diflucortolone Valerate)

Diflucortolone valerate, the active ingredient in Nerisona, is a corticosteroid presented as a topical formulation for cutaneous use. It is indicated for the treatment of inflammatory skin disorders such as psoriasis, eczema and dermatitis, helping to reduce redness, swelling and itching.

GNH USA supplies Nerisona as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Its global logistics network ensures timely delivery and compliance with local regulatory requirements.

Diflucortolone valerate is a potent topical corticosteroid used to manage inflammatory skin conditions.

- Psoriasis: reduces plaque formation and inflammation, improving skin appearance. - Eczema: alleviates redness, itching and swelling associated with atopic dermatitis. - Dermatitis: controls acute inflammatory reactions and promotes faster healing of affected skin.

Topical diflucortolone valerate may cause local reactions, especially with prolonged use.

Common Side Effects: - Burning sensation: transient discomfort at the application site. - Pruritus: mild itching may occur after application. - Dryness: skin may become less hydrated. - Erythema: mild redness of the treated area. - Folliculitis: inflammation of hair follicles. - Acneiform eruption: small pimples may develop.

Serious or Rare Side Effects: - Skin atrophy: thinning of the epidermis with long‑term use. - Telangiectasia: visible small blood vessels on the skin surface. - Secondary infection: bacterial or fungal infection of compromised skin. - Hypopigmentation: loss of skin colour in the treated area. - Systemic adrenal suppression: rare, due to extensive absorption. - Allergic contact dermatitis: immune‑mediated skin reaction.

When using diflucortolone valerate, follow these safety measures.

- Apply to affected area only: avoid healthy skin, eyes, and mucous membranes. - Duration of therapy: limit use to the prescribed period to reduce risk of skin atrophy. - Use with caution in children: monitor for systemic effects and adjust duration accordingly. - Avoid occlusive dressings unless directed: they can increase percutaneous absorption. - Pregnancy and lactation: consult a healthcare professional before use. - Store at room temperature: keep in the original container, protect from moisture and light.

Diflucortolone valerate may interact with other medications applied to the skin or taken systemically.

Major Interactions (Avoid): - Systemic corticosteroids: additive immunosuppression may increase infection risk. - Antifungal agents (e.g., ketoconazole): can raise local steroid concentration. - Photosensitizing drugs: heightened risk of phototoxic skin reactions.

Moderate Interactions (Monitor Closely): - Retinoids: may enhance local irritation and dryness. - Topical NSAIDs: potential for increased skin irritation. - Antibiotic ointments: monitor for signs of secondary infection.